<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRISENOX- arsenic trioxide injection, solution </strong><br>Cephalon, Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">TRISENOX</span> safely and effectively.  See full prescribing information for <span class="Bold">TRISENOX</span>.<br><span class="Bold">TRISENOX<span class="Sup">®</span> (arsenic trioxide) injection, for intravenous administration </span><br>Initial U.S. Approval: 2000</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  APL DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION <br>ABNORMALITIES, and AND ELECTROLYTE <br>MONITORING</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Patients have experienced symptoms similar to retinoic-acid-<span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">Acute Promyelocytic Leukemia</span> or APL differentiation syndrome, which can be fatal. If symptoms occur, initiate high-dose steroids immediately and continue for at least 3 days until symptoms have abated.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Arsenic trioxide can cause QT interval prolongation and complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>. QT prolongation can lead to a <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, which can be fatal.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Before intiating therapy, perform a 12-lead ECG, assess serum electrolytes and creatinine, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QT interval.</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  APL DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION <br>ABNORMALITIES, and AND ELECTROLYTE <br>MONITORING</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Patients have experienced symptoms similar to retinoic-acid-<span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">Acute Promyelocytic Leukemia</span> or APL differentiation syndrome, which can be fatal. If symptoms occur, initiate high-dose steroids immediately and continue for at least 3 days until symptoms have abated.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Arsenic trioxide can cause QT interval prolongation and complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>. QT prolongation can lead to a <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, which can be fatal.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Before intiating therapy, perform a 12-lead ECG, assess serum electrolytes and creatinine, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QT interval.</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">TRISENOX is an arsenical indicated for induction of remission and consolidation in patients with <span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">acute promyelocytic leukemia</span> (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.<br>  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>For induction therapy, administer intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Do not exceed 60 doses for total induction. (<a href="#ID_de3e7853-231d-4860-a16c-d7097c848608">2.1</a>)</dd>
<dt>•</dt>
<dd>Begin consolidation treatment 3 to 6 weeks after completion of induction therapy. Administer intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks. (<a href="#ID_de3e7853-231d-4860-a16c-d7097c848608">2.1</a>)</dd>
<dt>•</dt>
<dd>Delay treatment for severe non-hematologic adverse reactions. (<a href="#ID_69ef76d1-42d8-407d-a444-136901a3bfea">2.2</a>)</dd>
<dt>•</dt>
<dd>Dilute prior to use. (<a href="#ID_8a2bc8b8-ebc9-4d0f-920f-00cf932cfdd5">2.3</a>)</dd>
<dt>•</dt>
<dd>Administer intravenously over 1-2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. (<a href="#ID_8a2bc8b8-ebc9-4d0f-920f-00cf932cfdd5">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injectable solution for intravenous administration supplied as 10 mg/10 ml of arsenic trioxide in single-use ampules. (<a href="#ID_0557139b-dc1a-4192-9288-d2cdbfe83c75">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to arsenic. (<a href="#ID_8383fd12-c5d4-43b7-af1f-4e9b01e87b73">4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Cardiac Conduction Abnormalities: During TRISENOX therapy, maintain potassium, concentrations above 4 mEq/L and magnesium concentrations above 1.8 mg/dL. (<a href="#ID_d840a9d1-8ad4-4cc3-b6aa-a288c186a3ee">5.2</a>)</dd>
<dt>•</dt>
<dd>Carcinogenesis: Arsenic trioxide is a human carcinogen. Monitor patients for the development of second primary malignancies. (<a href="#ID_36521e2f-b3d4-448b-ada6-4b50e1580c0e">5.3</a>) </dd>
<dt>•</dt>
<dd>Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (<a href="#ID_662c8348-0482-47c2-a305-cb42b92327b1">5.4</a>, <a href="#ID_5aa7fcbc-22b5-47dc-8e09-10720f0f8697">8.1</a>, <a href="#ID_596b51dc-bf35-4be2-b83b-1c5d4ee667b1">8.3</a>) </dd>
<dt>•</dt>
<dd>Laboratory Tests: Monitor patient’s electrolyte, hematologic and coagulation profiles and obtain ECGs. (<a href="#ID_620e8520-ead4-4f92-9ed7-31294a0e5c73">5.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions in patients with relapsed or refractory APL were <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, gastrointestinal (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. (<a href="#ID_2f8136d8-5105-4eae-aedb-b47f85c67766">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-800-896-5855 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Lactation: Discontinue breastfeeding. (<a href="#ID_596b51dc-bf35-4be2-b83b-1c5d4ee667b1">8.2</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Monitor patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) for toxicity when treated with TRISENOX; dose reduction may be warranted. (<a href="#ID_94243e7e-79d3-4a6f-94ca-e97a3b1c53fb">8.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Monitor patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) for toxicity when treated with TRISENOX. (<a href="#ID_020ed674-b922-49a2-bd85-d9ed5d067e38">8.7</a>)<br>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: APL DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, AND ELECTROLYTE MONITORING</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Dose Adjustment for Non-Hematologic Adverse Reactions</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Instructions for Preparation and Intravenous Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Stability</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 APL Differentiation Syndrome</a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Cardiac Conduction Abnormalities: <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">Complete Heart Block</span>, and QT Prolongation</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Carcinogenesis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Manifestations</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Management</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage And Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-18.1" class="toc">Trisenox® (arsenic trioxide) Injection 1 mg/mL, 10 x 10 mL Ampules Carton Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_3f65564a-d7dc-417e-8208-7ec066606d68"></a><a name="section-1"></a><p></p>
<h1>WARNING: APL DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, AND ELECTROLYTE MONITORING</h1>
<p class="First"><span class="Bold">APL Differentiation Syndrome:</span> Patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic-acid-<span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">Acute Promyelocytic Leukemia</span> (RA-APL) or APL differentiation syndrome, characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, pulmonary infiltrates and pleural or <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusions</span>, with or without <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>. This syndrome can be fatal. High-dose steroids have been administered at the first suspicion of the APL differentiation syndrome and appear to mitigate signs and symptoms. At the first signs that could suggest the syndrome (unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, abnormal chest auscultatory findings or radiographic abnormalities), immediately initiate high-dose steroids (dexamethasone 10 mg intravenously BID) , irrespective of the leukocyte count, and continue for at least 3 days or longer until signs and symptoms have abated. The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome <span class="Italics">[see Warnings and Precautions (<a href="#ID_1874f80c-66ec-4921-a69e-5696382a210c">5.1</a>)].</span></p>
<p><span class="Bold">Cardiac Conduction Abnormalities:</span> Before initiating therapy, perform a 12-lead ECG, assess serum electrolytes and creatinine, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QT interval. Arsenic trioxide can cause QT interval prolongation and complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>. QT prolongation can lead to a <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, which can be fatal. The risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> is related to the extent of QT prolongation, concomitant administration of QT prolonging drugs, a history of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, preexisting QT interval prolongation, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, administration of potassium-<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span> diuretics, or other conditions that result in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. One patient (also receiving amphotericin B) had <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> during induction therapy for relapsed APL with arsenic trioxide <span class="Italics">[see Warnings and Precautions (<a href="#ID_d840a9d1-8ad4-4cc3-b6aa-a288c186a3ee">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_21b86573-e08d-4d44-a907-dbc9105d0e8b"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">TRISENOX is indicated for induction of remission and consolidation in patients with <span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">acute promyelocytic leukemia</span> (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_d7986b1a-fef3-45b8-8ab2-64840cddcd22"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_de3e7853-231d-4860-a16c-d7097c848608"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosage</h2>
<p class="First"><span class="Underline">Induction Treatment Schedule:</span> Administer TRISENOX intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Do not exceed 60 doses for induction. </p>
<p><span class="Underline">Consolidation Treatment Schedule:</span> Begin consolidation treatment 3 to 6 weeks after completion of induction therapy. Administer TRISENOX intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_69ef76d1-42d8-407d-a444-136901a3bfea"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Dose Adjustment for Non-Hematologic Adverse Reactions</span></h2>
<p class="First">If a severe non-hematologic adverse reaction occurs (such as neurologic or dermatologic toxicity), consider delaying TRISENOX infusion until the event has resolved (≤ Grade 1).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8a2bc8b8-ebc9-4d0f-920f-00cf932cfdd5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Instructions for Preparation and Intravenous Administration</h2>
<p class="First"><span class="Italics">Administration</span></p>
<p>Administer TRISENOX intravenously over 1-2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. A central venous catheter is not required.</p>
<p>The TRISENOX ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Do not mix TRISENOX with other medications.</p>
<p><span class="Italics">Reconstitution</span></p>
<p>Dilute TRISENOX with 100 to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. Do not save any unused portions for later administration.</p>
<p><span class="Italics">Safe Handling Procedures</span></p>
<p>TRISENOX is a cytotoxic drug. Follow applicable special handling and disposal procedures.<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f2cd15c-63e5-4d5b-a716-ff1c9aed8160"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Stability</h2>
<p class="First">After dilution, TRISENOX is chemically and physically stable when stored for 24 hours at room temperature and 48 hours when refrigerated.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_0557139b-dc1a-4192-9288-d2cdbfe83c75"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TRISENOX is an injectable solution for intravenous administration supplied as 10mg /10 ml of arsenic trioxide in single-use ampules.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_8383fd12-c5d4-43b7-af1f-4e9b01e87b73"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">TRISENOX is contraindicated in patients who are hypersensitive to arsenic.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_de0a2be2-d227-4085-a515-1dd60344d58e"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1874f80c-66ec-4921-a69e-5696382a210c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 APL Differentiation Syndrome</h2>
<p class="First">Nine of 40 patients with APL treated with TRISENOX, at a dose of 0.15 mg/kg, experienced the APL differentiation syndrome. High-dose steroids have been administered at the first suspicion of the APL differentiation syndrome and appear to mitigate signs and symptoms. At the first signs that could suggest the syndrome (unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, abnormal chest auscultatory findings or radiographic abnormalities), high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated, irrespective of the leukocyte count, and continued for at least 3 days or longer until signs and symptoms have abated. The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome. <span class="Italics">[see Adverse Reactions (<a href="#ID_907d1d31-ded6-4c40-8ecb-6acbe6118a00">6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d840a9d1-8ad4-4cc3-b6aa-a288c186a3ee"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Cardiac Conduction Abnormalities: <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">Complete Heart Block</span>, and QT Prolongation</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de pointes</span> and <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> have been reported. QT/QTc prolongation can occur. Sixteen of 40 patients (40%) had at least one ECG tracing with a QTc interval greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after TRISENOX infusion, and then returned towards baseline by the end of 8 weeks after TRISENOX infusion.</p>
<p>Prior to initiating therapy with TRISENOX, a 12-lead ECG should be performed and serum electrolytes (potassium, calcium, and magnesium) and creatinine should be assessed. Preexisting electrolyte abnormalities should be corrected and, if possible, drugs that are known to prolong the QT interval should be discontinued. If it’s not possible to discontinue the interacting drug, perform cardiac monitoring frequently <span class="Italics">[see Drug Interactions (<a href="#ID_faa50596-6588-4313-9f03-1dd66f6ac043">7</a>)].</span></p>
<p>Monitor ECG weekly, and more frequently for clinically unstable patients.</p>
<p>For QTc greater than 500 msec, complete corrective measures and reassess the QTc with serial ECGs prior to initiating TRISENOX. During TRISENOX therapy, maintain potassium concentrations above 4 mEq/L and magnesium concentrations above 1.8 mg/dL. Reassess patients who reach an absolute QT interval value &gt; 500 msec and immediately correct concomitant risk factors, if any, while the risk/benefit of continuing versus suspending TRISENOX therapy should be considered. There are no data on the effect of TRISENOX on the QTc interval during the infusion.</p>
<p>The risk may be increased when TRISENOX is coadministered with medications that can lead to electrolyte abnormalities (such as diuretics or amphotericin B) <span class="Italics">[see Drug Interactions (<a href="#ID_faa50596-6588-4313-9f03-1dd66f6ac043">7</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36521e2f-b3d4-448b-ada6-4b50e1580c0e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Carcinogenesis</h2>
<p class="First">The active ingredient of TRISENOX, arsenic trioxide, is a human carcinogen. Monitor patients for the development of second primary malignancies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_662c8348-0482-47c2-a305-cb42b92327b1"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Embryo-Fetal Toxicity</h2>
<p class="First">TRISENOX can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m² basis. A related trivalent arsenic, sodium arsenite, produced <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m² basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m² basis. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and after treatment with TRISENOX <span class="Italics">[</span>see<span class="Italics"></span><span class="Italics">Use in Specific Populations (<a href="#ID_5aa7fcbc-22b5-47dc-8e09-10720f0f8697">8.1</a>,<a href="#ID_3e86fa01-b216-4558-9648-eea1dcfbaa87">8.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_620e8520-ead4-4f92-9ed7-31294a0e5c73"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Laboratory Tests</h2>
<p class="First">The patient’s electrolyte and glucose levels, as well as hepatic, renal, hematologic and coagulation profiles should be monitored at least twice weekly, and more frequently for clinically unstable patients during the induction phase and at least weekly during the consolidation phase.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_907d1d31-ded6-4c40-8ecb-6acbe6118a00"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions have been associated with TRISENOX in clinical trials and are discussed in greater detail in other sections of the label.</p>
<dl>
<dt>•</dt>
<dd>APL Differentiation Syndrome<span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_1874f80c-66ec-4921-a69e-5696382a210c">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Cardiac Conduction Abnormalities: <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">Complete Heart Block</span>, and QT Prolongation <span class="Italics">[see Warnings and Precautions (<a href="#ID_d840a9d1-8ad4-4cc3-b6aa-a288c186a3ee">5.2</a>)]</span>
</dd>
<dt>•</dt>
<dd>Carcinogenesis <span class="Italics">[see Warnings and Precautions (<a href="#ID_36521e2f-b3d4-448b-ada6-4b50e1580c0e">5.3</a>)]</span>
</dd>
<dt>•</dt>
<dd>Embryo-Fetal Toxicity <span class="Italics">[see Warnings and Precautions (<a href="#ID_662c8348-0482-47c2-a305-cb42b92327b1">5.4</a>)]</span>
</dd>
<dt>•</dt>
<dd>Laboratory Tests <span class="Italics">[see Warnings and Precautions (<a href="#ID_620e8520-ead4-4f92-9ed7-31294a0e5c73">5.5</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f8136d8-5105-4eae-aedb-b47f85c67766"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Safety information was available for 52 patients with relapsed or refractory APL who participated in clinical trials of TRISENOX. Forty patients in the Phase 2 study received the recommended dose of 0.15 mg/kg of which 28 completed both induction and consolidation treatment cycles. An additional 12 patients with relapsed or refractory APL received doses generally similar to the recommended dose. Most patients experienced some drug-related toxicity, most commonly <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, gastrointestinal (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. These adverse effects have not been observed to be permanent or irreversible nor do they usually require interruption of therapy.</p>
<p>Serious adverse events (SAEs), Grade 3/4 according to version 2 of the NCI Common Toxicity Criteria, were common. Those SAEs attributed to TRISENOX in the Phase 2 study of 40 patients with refractory or relapsed APL included APL differentiation syndrome (n=3), hyperleukocytosis (n=3), QTc interval ≥ 500 msec (n=16, 1 with <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>), atrial <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> (n=2), and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (n=2).</p>
<p>Table 1 describes the adverse events that were observed in patients, between the ages of 5-73 years, treated for APL with TRISENOX at the recommended dose at a rate of 5% or more. Similar adverse event profiles were seen in the other patient populations who received TRISENOX.</p>
<p><span class="Bold">Table 1 </span></p>
<p><span class="Bold">Adverse Events (Any Grade) Occurring in ≥ 5% of 40 Patients with APL Who Received </span></p>
<p><span class="Bold">TRISENOX (arsenic trioxide) Injection at a Dose of 0.15 mg/kg/day</span></p>
<table width="100%">
<col width="46%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2">
<p class="First"><span class="Bold">System organ class</span></p>
<p><span class="Bold"></span>Adverse event</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">All Adverse Events,</span></p>
<p><span class="Bold">Any Grade</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Grade 3/4 Events</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">General disorders and administration site conditions</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">63</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">63</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> - non-specific</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> - non-specific</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection site edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">75</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite decreased</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> (lower &amp; upper)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Oral <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">Fecal incontinence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">Abdominal tenderness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">Diarrhea hemorrhagic</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Metabolism and nutrition disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">45</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   ALT increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   AST increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">65</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Post nasal drip</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Decreased breath sounds</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Crepitations</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">Rhonchi</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Skin &amp; subcutaneous tissue disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> - non-specific</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Hyperpigmentation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Non-specific <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Local <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">Eyelid edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">   ECG QT corrected interval prolonged </p>
<p>   &gt; 500 msec</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">ECG abnormal</span> other than QT interval<br>   prolongation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Herpes simplex</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial infection</span> - non-specific</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Musculoskeletal, connective tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Hematologic disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated intravascular coagulation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Psychiatric disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Ocular disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eye</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   Painful <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eye</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Renal and urinary disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Reproductive system disorders</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">Intermenstrual bleeding</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">Ear disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Earache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">   <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
</tbody>
</table>
<p>The following additional adverse events were reported as related to TRISENOX treatment in 13 pediatric patients (defined as ages 4 through 20): gastrointestinal (<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>/<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">caecitis</span>), metabolic and nutrition disorders (<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and lipase increased), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">cardiac failure congestive</span>, respiratory (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">capillary leak syndrome</span>), <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, and <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>. <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> (n=1) and <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">caecitis</span> (n=1) were considered serious reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a086cb2b-b344-4f97-8073-f372922802dc"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following reactions have been reported from clinical trials and/or worldwide postmarketing surveillance. Because they are reported from a population of unknown size, precise estimates of frequency cannot be made.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span> in association with QT prolongation, and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> in association with QT prolongation.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span></p>
<p><span class="Bold">Hematologic disorders:</span> <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Bold">Investigations: </span>gamma-glutamyltransferase increased</p>
<p><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> A differentiation syndrome, like <span class="product-label-link" type="condition" conceptid="42872892" conceptname="Retinoic acid syndrome">retinoic acid syndrome</span>, has been reported with the use of TRISENOX for the treatment of malignancies other than APL <span class="Italics">[see <a href="#ID_3f65564a-d7dc-417e-8208-7ec066606d68">Boxed Warning</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_faa50596-6588-4313-9f03-1dd66f6ac043"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">Drugs That Can Prolong the QT/QTc Interval </span>Concomitant use of these drugs and TRISENOX may increase the risk of serious QT/QTc interval prolongation. Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while patient is using TRISENOX. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use.   </p>
<p><span class="Italics">Drugs That Can Lead to Electrolyte Abnormalities </span>Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation. Avoid concomitant administration of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and TRISENOX.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_315260eb-f7a1-4ba3-b02a-f4349545e658"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_5aa7fcbc-22b5-47dc-8e09-10720f0f8697"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>TRISENOX can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m² basis [<span class="Italics">see Data</span>]. A related trivalent arsenic, sodium arsenite, produced <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m² basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m² basis. There are no studies in pregnant women using TRISENOX. Advise pregnant women of the potential risk to a fetus.</p>
<p>The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated population is unknown. However, the background risk in the U.S. general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2-4% and of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15-20% of clinically recognized pregnancies. </p>
<p><span class="Italics">Data</span></p>
<p><span class="Underline">Human Data</span></p>
<p>One patient who became pregnant while receiving arsenic trioxide had a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>.</p>
<p><span class="Underline">Animal Data</span></p>
<p>Studies in pregnant mice, rats, hamsters, and primates have shown that inorganic arsenicals cross the placental barrier when given orally or by injection. An increase in resorptions, neural-tube defects, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span> and <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span> were observed in rats administered 10 mg/kg of arsenic trioxide on gestation day 9 (approximately 10 times the recommended human daily dose on a mg/m² basis). Similar findings occurred in mice administered a 10 mg/kg dose of a related trivalent arsenic, sodium arsenite (approximately 5 times the projected human dose on a mg/m² basis), on gestation days 6, 7, 8 or 9. Intravenous injection of 2 mg/kg sodium arsenite (approximately equivalent to the projected human daily dose on a mg/m² basis) on gestation day 7 (the lowest dose tested) resulted in neural-tube defects in hamsters.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_596b51dc-bf35-4be2-b83b-1c5d4ee667b1"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation</h2>
<p class="First">Arsenic is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from TRISENOX, discontinue breastfeeding during treatment with TRISENOX.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_3e86fa01-b216-4558-9648-eea1dcfbaa87"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Females and Males of Reproductive Potential</h2>
<p class="First"><span class="Italics">Contraception</span></p>
<p><span class="Underline">Females</span></p>
<p>TRISENOX can cause fetal harm when administered to a pregnant woman <span class="Italics">[</span>see <span class="Italics">Use in Specific Populations (<a href="#ID_5aa7fcbc-22b5-47dc-8e09-10720f0f8697">8.1</a>)]</span>. Advise females of reproductive potential to use effective contraception during and after treatment with TRISENOX.</p>
<p><span class="Underline">Males</span></p>
<p>Males with female sexual partners of reproductive potential should use effective contraception during and after treatment with TRISENOX.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_7be97a5a-d353-4f49-beb6-f5671a7e5a6b"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">There are limited clinical data on the pediatric use of TRISENOX. Of 5 patients below the age of 18 years (age range: 5 to 16 years) treated with TRISENOX, at the recommended dose of 0.15 mg/kg/day, 3 achieved a complete response. </p>
<p>In an additional study, the toxicity profile observed in 13 pediatric patients with APL between the ages of 4 and 20 receiving TRISENOX at 0.15 mg/kg/day was similar to that observed in adult patients <span class="Italics">[see<span class="Bold"></span>Adverse Reactions</span><span class="Bold"></span><span class="Italics">(<a href="#ID_2f8136d8-5105-4eae-aedb-b47f85c67766">6.1</a>)]. </span>No children less than 4 years of age were enrolled in the trial due to the rarity of APL in this age group.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_94243e7e-79d3-4a6f-94ca-e97a3b1c53fb"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of TRISENOX (arsenic trioxide) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Monitor elderly patients closely, reflecting the greater frequency of decreased hepatic and renal function, concomitant disease or other drug therapy in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf5766d3-efb3-47ec-864c-b10c48105583"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Exposure of arsenic trioxide may be higher in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see<span class="Bold"></span>Clinical Pharmacology</span><span class="Bold"></span><span class="Italics">(<a href="#ID_2a6bb157-56e8-4f39-b789-9efb79b9e53c">12.3</a>)]</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) should be monitored for toxicity when these patients are treated with TRISENOX, and a dose reduction may be warranted.</p>
<p>The use of TRISENOX in patients on dialysis has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_020ed674-b922-49a2-bd85-d9ed5d067e38"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Since limited data are available across all <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> groups, caution is advised in the use of TRISENOX in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see</span><span class="Bold"></span><span class="Italics">Clinical Pharmacology</span><span class="Bold"></span><span class="Italics">(<a href="#ID_2a6bb157-56e8-4f39-b789-9efb79b9e53c">12.3</a>)]</span>. Monitor patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) who are treated with TRISENOX for toxicity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_e27efc8e-eb81-48f5-8445-eb493cec20f7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3ac1d7f8-bdb6-44ec-a53f-be20ab75bde9"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Manifestations</h2>
<p class="First">Manifestations of TRISENOX (arsenic trioxide) overdosage include <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8fd1904b-4d4a-4eca-8a33-964b07937f2b"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Management</h2>
<p class="First">If symptoms of TRISENOX (arsenic trioxide) overdosage develop, the injection should be immediately discontinued and chelation therapy should be considered.</p>
<p>A conventional protocol for acute arsenic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> includes dimercaprol administered at a dose of 3 mg/kg intramuscularly every 4 hours until immediate life-threatening toxicity has subsided. Thereafter, penicillamine at a dose of 250 mg orally, up to a maximum frequency of four times per day (≤ 1 g per day), may be given.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_8b20cb81-a2d3-44e6-9e51-927648fccf39"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TRISENOX is a sterile injectable solution of arsenic trioxide. The molecular formula of the drug substance in the solid state is As<span class="Sub">2</span>O<span class="Sub">3</span>, with a molecular weight of 197.8 and has the following structural formula:</p>
<div class="Figure">
<a name="id-121453315"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dec51fab-3784-deb7-752f-2d4d5692a20f&amp;name=image-01.jpg">
</div>
<p>TRISENOX is available in 10 mL, single-use ampules containing 10 mg of arsenic trioxide. TRISENOX is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. TRISENOX is preservative-free. Arsenic trioxide, the active ingredient, is present at a concentration of 1.0 mg/mL. Inactive ingredients and their respective approximate concentrations are sodium hydroxide (1.2 mg/mL) and hydrochloric acid, which is used to adjust the pH to 7.5 - 8.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_2c8b234b-28e7-486e-a08f-4de319c1ba26"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_13f491cf-2f02-4e29-a2d5-5f8e7d0eb4a8"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of TRISENOX is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> in NB4 human promyelocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (PML)-retinoic acid receptor (RAR)-alpha.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_00cf694d-7d62-4aac-bc6e-481b64def902"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Italics">Cardiac Electrophysiology</span></p>
<p>A dedicated QTc study was not performed with Trisenox. However, in a single arm trial of Trisenox (0.15 mg/kg daily), 16 of 40 patients (40%) had a QTc interval greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after TRISENOX infusion, and then returned towards baseline by the end of 8 weeks after TRISENOX infusion.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_2a6bb157-56e8-4f39-b789-9efb79b9e53c"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (As<span class="Sup">III</span>). As<span class="Sup">III</span> is the pharmacologically active species of arsenic trioxide. Monomethylarsonic acid (MMA<span class="Sup">V</span>), and dimethylarsinic acid (DMA<span class="Sup">V</span>) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (As<span class="Sup">V</span>) a product of As<span class="Sup">III</span> oxidation. The pharmacokinetics of arsenical species ([As<span class="Sup">III</span>], [As<span class="Sup">V</span>], [MMA<span class="Sup">V</span>], [DMA<span class="Sup">V</span>]) were determined in 6 APL patients following once daily doses of 0.15 mg/kg for 5 days per week. Over the total single dose range of 7 to 32 mg (administered as 0.15 mg/kg), systemic exposure (AUC) appears to be linear. Peak plasma concentrations of arsenious acid (As<span class="Sup">III</span>), the primary active arsenical species were reached at the end of infusion (2 hours). Plasma concentration of As<span class="Sup">III</span> declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase. The daily exposure to As<span class="Sup">III</span> (mean AUC<span class="Sub">0-24</span>) was 194 ng·hr/mL (n=5) on Day 1 of Cycle 1 and 332 ng·hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation. The primary pentavalent metabolites, MMA<span class="Sup">V</span> and DMA<span class="Sup">V</span>, are slow to appear in plasma (approximately 10-24 hours after first administration of arsenic trioxide), but, due to their longer half-life, accumulate more upon multiple dosing than does As<span class="Sup">III</span>. The mean estimated terminal elimination half-lives of the metabolites MMA<span class="Sup">V</span> and DMA<span class="Sup">V</span> are 32 hours and 72 hours, respectively.  Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single dose administration. As<span class="Sup">V </span>is present in plasma only at relatively low levels.</p>
<p><span class="Underline">Distribution</span></p>
<p>The volume of distribution (V<span class="Sub">ss</span>) for As<span class="Sup">III</span> is large (mean 562 L, N=10) indicating that As<span class="Sup">III</span> is widely distributed throughout body tissues.  V<span class="Sub">ss</span> is also dependent on body weight and increases as body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increases</span>. </p>
<p><span class="Underline">Metabolism </span></p>
<p>Much of the As<span class="Sup">III</span> is distributed to the tissues where it is methylated to the less cytotoxic metabolites, monomethylarsonic acid (MMA<span class="Sup">V</span>) and dimethylarsinic acid (DMA<span class="Sup">V</span>) by methyltransferases primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of As<span class="Sup">III</span> to As<span class="Sup">V</span>, which may occur in numerous tissues via enzymatic or nonenzymatic processes.  As<span class="Sup">V</span> is present in plasma only at relatively low levels<span class="Bold"></span>following administration of arsenic trioxide.</p>
<p><span class="Underline">Excretion</span></p>
<p>Approximately 15% of the administered TRISENOX dose is excreted in the urine as unchanged As<span class="Sup">III</span>. The methylated metabolites of As<span class="Sup">III</span> (MMA<span class="Sup">V</span>, DMA<span class="Sup">V</span>) are primarily excreted in the urine. The total clearance of As<span class="Sup">III</span> is 49 L/h and the renal clearance is 9 L/h. Clearance is not dependent on body weight or dose administered over the range of 7-32 mg.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of As<span class="Sup">III</span>, As<span class="Sup">V</span>, and the pentavalent metabolites MMA<span class="Sup">V</span> and DMA<span class="Sup">V</span> was evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CrCl] &gt; 80 mL/min, n=6), mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 50-80 mL/min, n=5), moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 30-49 mL/min, n=6), or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt; 30 mL/min, n=3). Following twice weekly administration of 0.15 mg/kg over a 2-hour infusion, the mean AUC<span class="Sub">0-∞</span> for As<span class="Sup">III</span> was comparable among the normal, mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> groups. However, in the <span class="Bold">severe</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> group, the mean AUC<span class="Sub">0-∞</span> for As<span class="Sup">III</span> was approximately 48% higher than that in the normal group.</p>
<p>Systemic exposure to MMA<span class="Sup">V</span> and DMA<span class="Sup">V </span>tended to be larger in patients with renal<span class="Sup"></span>impairment; however, the clinical consequences of this increased exposure are not known. As<span class="Sup">V</span> plasma levels were generally below the limit of assay quantitation in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see Use in Specific Populations (<a href="#ID_bf5766d3-efb3-47ec-864c-b10c48105583">8.6</a>)]</span>. The use of arsenic trioxide in patients on dialysis has not been studied. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The effect of pharmacokinetics of As<span class="Sup">III</span>, As<span class="Sup">V</span>, and the pentavalent metabolites MMA<span class="Sup">V</span> and DMA<span class="Sup">V </span>was evaluated following administration of 0.25-0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function (n=4), mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class A, n=12), moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class B, n=3), or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C, n=1). No clear trend toward an increase in systemic exposure to As<span class="Sup">III</span>, As<span class="Sup">V</span>, MMA<span class="Sup">V</span> or DMA<span class="Sup">V </span>was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC in the mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> groups. However, the one patient with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had mean dose-normalized AUC<span class="Sub">0‑24</span> and C<span class="Sub">max</span> values 40% and 70% higher, respectively, than those patients with normal hepatic function. The mean dose-normalized trough plasma levels for both MMA<span class="Sup">V</span> and DMA<span class="Sup">V</span> in this severely hepatically impaired patient were 2.2-fold and 4.7-fold higher, respectively, than those in the patients with normal hepatic function <span class="Italics">[see</span><span class="Italics">Use in Specific Populations (<a href="#ID_020ed674-b922-49a2-bd85-d9ed5d067e38">8.7</a>)]</span>.</p>
<p><span class="Underline">Pediatric Patients</span></p>
<p>Following IV administration of 0.15 mg/kg/day of arsenic trioxide in 10 APL patients (median age = 13.5 years, range 4-20 years), the daily exposure to As<span class="Sup">III </span>(mean AUC<span class="Sub">0-24h</span>) was 317 ng·hr/mL on Day 1 of Cycle 1 <span class="Italics">[see</span><span class="Italics">Use in Specific Populations (<a href="#ID_7be97a5a-d353-4f49-beb6-f5671a7e5a6b">8.4</a>)]</span>. </p>
<p><span class="Underline">Drug Interactions</span></p>
<p>No formal assessments of pharmacokinetic drug-drug interactions between TRISENOX and other drugs have been conducted. The methyltransferases responsible for metabolizing arsenic trioxide are not members of the cytochrome P450 family of isoenzymes. In vitro incubation of arsenic trioxide with human liver microsomes showed no inhibitory activity on substrates of the major cytochrome P450 (CYP) enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11. The pharmacokinetics of drugs that are substrates for these CYP enzymes are not expected to be affected by concomitant treatment with arsenic trioxide. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_5aae4de8-c226-4059-92fa-9201fd2f8553"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_9ed353a1-b719-4b71-af85-c0678ce18d8e"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with TRISENOX by intravenous administration <span class="Italics">[see Warnings and Precautions (<a href="#ID_662c8348-0482-47c2-a305-cb42b92327b1">5.4</a>)].</span></p>
<p>Arsenic trioxide and trivalent arsenite salts have not been demonstrated to be mutagenic to bacteria, yeast or mammalian cells. Arsenite salts are clastogenic in vitro (human fibroblast, human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, Chinese hamster ovary cells, Chinese hamster V79 lung cells). Trivalent arsenic produced an increase in the incidence of chromosome aberrations and micronuclei in bone marrow cells of mice. </p>
<p>The effect of arsenic on fertility has not been adequately studied<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_0801a85b-eeae-4c9b-99fd-cb39bec2c961"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">TRISENOX has been investigated in 40 relapsed or refractory APL patients, previously treated with an anthracycline and a retinoid regimen, in an open-label, single-arm, non-comparative study. Patients received 0.15 mg/kg/day intravenously over 1 to 2 hours until the bone marrow was cleared of leukemic cells or up to a maximum of 60 days. The CR (absence of visible leukemic cells in bone marrow and peripheral recovery of platelets and white blood cells with a confirmatory bone marrow ≥ 30 days later) rate in this population of previously treated patients was 28 of 40 (70%). Among the 22 patients who had relapsed less than one year after treatment with ATRA, there were 18 complete responders (82%). Of the 18 patients receiving TRISENOX ≥ one year from ATRA treatment, there were 10 complete responders (55%). The median time to bone marrow remission was 44 days and to onset of CR was 53 days. Three of 5 children, 5 years or older, achieved CR. No children less than 5 years old were treated. </p>
<p>Three to six weeks following bone marrow remission, 31 patients received consolidation therapy with TRISENOX, at the same dose, for 25 additional days over a period up to 5 weeks. In follow-up treatment, 18 patients received further arsenic trioxide as a maintenance course. Fifteen patients had bone marrow transplants. At last follow-up, 27 of 40 patients were alive with a median follow-up time of 484 days (range 280 to 755) and 23 of 40 patients remained in complete response with a median follow-up time of 483 days (range 280 to 755).</p>
<p>Cytogenetic conversion to no detection of the APL chromosome rearrangement was observed in 24 of 28 (86%) patients who met the response criteria defined above, in 5 of 5 (100%) patients who met some but not all of the response criteria, and 3 of 7 (43%) of patients who did not respond. RT-PCR conversions to no detection of the APL gene rearrangement were demonstrated in 22 of 28 (79%) of patients who met the response criteria, in 3 of 5 (60%) of patients who met some but not all of the response criteria, and in 2 of 7 (29%) of patients who did not respond.</p>
<p>Hyperleukocytosis (≥ 10 x 10³/uL) developed in 20 of the 40 patients treated.  A relationship did not exist between baseline WBC counts and development of hyperleukocytosis nor baseline WBC counts and peak WBC counts. Hyperleukocytosis was not treated with additional chemotherapy. WBC counts during consolidation were not as high as during induction treatment.</p>
<p>Responses were seen across all age groups tested, ranging from 6 to 72 years. The ability to achieve a CR was similar for both genders. There were insufficient patients of Black, Hispanic or Asian derivation to estimate relative response rates in these groups, but responses were seen in members of each group. </p>
<p>Another single center study in 12 patients with relapsed or refractory APL, where patients received TRISENOX (arsenic trioxide) injection doses generally similar to the recommended dose, had similar results with 9 of 12 (75%) patients attaining a CR.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_6bb5f009-6170-4a3f-9434-f06bbc9ff08b"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>“Hazardous Drugs?, <span class="Italics">OSHA.</span> [Accessed on February 12, 2015 from <a href="http://www.osha.gov/SLTC/hazardousdrugs/index.html">http://www.osha.gov/SLTC/hazardousdrugs/index.html</a>]</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_ecec2273-c588-47b8-a353-7f07c6235cfe"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a54ddc37-7989-49b2-b7aa-297d28e97c0c"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">TRISENOX (arsenic trioxide) injection is supplied as a sterile, clear, colorless solution in 10 mL glass, single-use ampules.</p>
<p><span class="Bold">NDC 63459-600-10</span> 10 mg/10 mL (1 mg/mL) ampule in packages of ten ampules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5c0ad51f-28b5-436c-93d8-a9757e8f0a68"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage And Handling</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15 - 30°C (59 - 86°F). Do not freeze.</p>
<p>TRISENOX is a cytotoxic drug. Follow applicable special handling and disposal procedures.<span class="Sup">1</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_0e7f6514-8da1-4591-95e6-fe5b480795d5"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>
<span class="Underline">APL Differentiation Syndrome</span><br>Advise patients that symptoms of APL differentiation syndrome include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, labored breathing, and accumulation of fluid in the lungs, heart, and chest. This syndrome is managed by immediate treatment with high dose corticosteroids. Advise patients to immediately report any of these symptoms.<br>
</dd>
<dt>•</dt>
<dd>
<span class="Underline">ECG Abnormalities – QT Prolongation</span><br>Advise patients that TRISENOX may cause ECG abnormalities, including QT prolongation.  QT prolongation is an increase in the time it takes the heart to relax between beats. If extreme, this prolongation has the potential to cause <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, irregular heart beat, or more serious side effects. Advise patients to immediately report any of these symptoms. Advise patients to provide a complete list of current medications as caution should be taken when TRISENOX is coadministered with other medications that can cause QT prolongation or lead to electrolyte abnormalities.<br>
</dd>
<dt>•</dt>
<dd>
<span class="Underline">Other Side Effects</span><br>Advise patients of the expected adverse reactions of TRISENOX. Most patients in clinical trials experienced some drug-related toxicity, most commonly <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. These adverse reactions have not been observed to be permanent or irreversible, nor do they usually require interruption of therapy. Advise patients to call their physician at the onset of any treatment-related adverse reactions.<br>
</dd>
<dt>•</dt>
<dd>
<span class="Underline">Embryo-Fetal Toxicity</span><br>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions 5.5 and Use in Specific Populations <span class="Underline"><a href="#ID_5aa7fcbc-22b5-47dc-8e09-10720f0f8697">8.1</a></span>)].<br>Advise females and males of reproductive potential to use effective contraception during and after treatment with TRISENOX [see Use in Specific Populations (<span class="Underline"><a href="#ID_3e86fa01-b216-4558-9648-eea1dcfbaa87">8.3</a></span>)].<br>
</dd>
<dt>•</dt>
<dd>
<span class="Underline">Lactation</span><br>Advise females to discontinue breastfeeding during treatment with TRISENOX [see Use in Specific Populations (<span class="Underline"><a href="#ID_596b51dc-bf35-4be2-b83b-1c5d4ee667b1">8.2</a></span>)].</dd>
</dl>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Distributed by:</p>
<p>Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA 19454</p>
<p>TRISENOX is a trademark of Cephalon, Inc. or its affiliates.</p>
<p>©2000-2015 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd, or its affiliates.</p>
<p></p>
<p>All rights reserved.</p>
<p>TRI-008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_91b748dd-6963-4dcf-8af2-201173836eb8"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel, Part 1 of 2</h1>
<div class="Figure">
<a name="id974791632"></a><img alt="Trisenox® (arsenic trioxide) Injection 1 mg/mL, 10 x 10 mL Ampules Carton, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dec51fab-3784-deb7-752f-2d4d5692a20f&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a1439112-d347-4a8f-b445-012c2c3107cf"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel, Part 2 of 2</h1>
<div class="Figure">
<a name="id974791634"></a><img alt="Trisenox® (arsenic trioxide) Injection 1 mg/mL, 10 x 10 mL Ampules Carton, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dec51fab-3784-deb7-752f-2d4d5692a20f&amp;name=image-03.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50867b76-6784-43c2-834a-2b1836160ccb"></a><a name="section-18.1"></a><p></p>
<h2>Trisenox® (arsenic trioxide) Injection 1 mg/mL, 10 x 10 mL Ampules Carton Text</h2>
<p class="First"><span class="Bold">NDC</span> 63459-600-10<span class="Bold">	10 x 10 mL ampules</span></p>
<p><span class="Bold">Trisenox</span>®<br>(arsenic trioxide)<br>injection</p>
<p><span class="Bold">10 mg/10 mL (1 mg/mL)</span></p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p>Rx only</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRISENOX 		
					</strong><br><span class="contentTableReg">arsenic trioxide injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63459-600</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ARSENIC TRIOXIDE</strong> (ARSENIC CATION (3+)) </td>
<td class="formItem">ARSENIC TRIOXIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63459-600-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">10/15/2000</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63459-600-01</td>
<td class="formItem">10 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021248</td>
<td class="formItem">10/15/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cephalon, Incorporated
							(183236314)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5e59e1c7-55ea-4e73-bf5b-00a8d1982c8c</div>
<div>Set id: dec51fab-3784-deb7-752f-2d4d5692a20f</div>
<div>Version: 6</div>
<div>Effective Time: 20150528</div>
</div>
</div> <div class="DistributorName">Cephalon, Incorporated</div></p>
</body></html>
